Abstract
RON (Receptuer dOrigine Nantaise) is a member of the MET receptor tyrosine kinase family. RON is expressed in various cell types including macrophages, epithelial and hematopoietic cells. Its ligand, macrophage stimulating protein (MSP, also known as hepatocyte growth factor-like protein), is a multifunctional factor regulating cell growth and survival, adhesion and motility, cytokine production and phagocytosis. Accumulated data indicate that in addition to the regulation of normal cell functions, RON can be involved in cancer development and progression: (i) RON is overexpressed and constitutively active in some primary tumors and tumor cell lines, (ii) experimental mutations of RON cause oncogenic cell transformation, and (iii) RON mediates susceptibility to Friend-virus-induced erythroleukemia in mice. Constitutive activation of intracellular signaling pathways such as the PI-3 kinase / AKT, beta-catenin, MAPK and JNK pathways may underlie the molecular mechanism of RON-mediated oncogenic cell transformation. The present review describes RON-activated signaling pathways, which may play an important role in tumor formation and metastasis.
Keywords: oncogenic signaling, ron, met receptor, ron receptor tyrosine kinase
Current Cancer Drug Targets
Title: Oncogenic Signaling Pathways Activated by RON Receptor Tyrosine Kinase
Volume: 3 Issue: 1
Author(s): Alla Danilkovitch-Miagkova
Affiliation:
Keywords: oncogenic signaling, ron, met receptor, ron receptor tyrosine kinase
Abstract: RON (Receptuer dOrigine Nantaise) is a member of the MET receptor tyrosine kinase family. RON is expressed in various cell types including macrophages, epithelial and hematopoietic cells. Its ligand, macrophage stimulating protein (MSP, also known as hepatocyte growth factor-like protein), is a multifunctional factor regulating cell growth and survival, adhesion and motility, cytokine production and phagocytosis. Accumulated data indicate that in addition to the regulation of normal cell functions, RON can be involved in cancer development and progression: (i) RON is overexpressed and constitutively active in some primary tumors and tumor cell lines, (ii) experimental mutations of RON cause oncogenic cell transformation, and (iii) RON mediates susceptibility to Friend-virus-induced erythroleukemia in mice. Constitutive activation of intracellular signaling pathways such as the PI-3 kinase / AKT, beta-catenin, MAPK and JNK pathways may underlie the molecular mechanism of RON-mediated oncogenic cell transformation. The present review describes RON-activated signaling pathways, which may play an important role in tumor formation and metastasis.
Export Options
About this article
Cite this article as:
Danilkovitch-Miagkova Alla, Oncogenic Signaling Pathways Activated by RON Receptor Tyrosine Kinase, Current Cancer Drug Targets 2003; 3 (1) . https://dx.doi.org/10.2174/1568009033333745
DOI https://dx.doi.org/10.2174/1568009033333745 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Transcriptional Control of Collagen I Gene Expression
Cardiovascular & Hematological Disorders-Drug Targets The Impact of Gynecological Cancer on Reproductive Issues and Pregnancy:Psychological Implications
Current Women`s Health Reviews Serotonin as a Modulator of Immune Function: An Overview
Current Immunology Reviews (Discontinued) New Perspectives in Glioma Immunotherapy
Current Pharmaceutical Design Preface
Current Molecular Medicine Folate Nutrigenetics: A Convergence of Dietary Folate Metabolism, Folic Acid Supplementation, and Folate Antagonist Pharmacogenetics
Drug Metabolism Letters Effects of Maternal Obesity and Gestational Diabetes Mellitus on the Placenta: Current Knowledge and Targets for Therapeutic Interventions
Current Vascular Pharmacology Passive Targeting of Cyclophosphamide-Loaded Carbonate Apatite Nanoparticles to Liver Impedes Breast Tumor Growth in a Syngeneic Model
Current Pharmaceutical Design Targeting the Folate Receptor: Improving Efficacy in Inorganic Medicinal Chemistry
Current Medicinal Chemistry An overview of ABC and SLC Drug Transporter Gene Regulation
Current Drug Metabolism Natural Products Based Anticancer Agents
Mini-Reviews in Organic Chemistry DNA Damage Repair and Response Proteins as Targets for Cancer Therapy
Current Medicinal Chemistry New Prognostic Markers and Potential Therapeutic Targets in Human Testicular Germ Cell Tumors
Current Medicinal Chemistry Treatment for Diabetic Peripheral Neuropathy: What have we Learned from Animal Models?
Current Diabetes Reviews Dihydrofolate Reductase Gene Variations in Susceptibility to Disease and Treatment Outcomes
Current Genomics Membrane Fusion Mediated Targeted Cytosolic Drug Delivery Through scFv Engineered Sendai Viral Envelopes
Current Molecular Medicine Recent Progress in Research on Ribosome Inactivating Proteins
Current Protein & Peptide Science Heterocyclic Scaffolds: Centrality in Anticancer Drug Development
Current Drug Targets Search for New and Novel Chemotherapeutics for the Treatment of Human Malignancies
Mini-Reviews in Medicinal Chemistry Damage and Recovery of the Bone Marrow Microenvironment Induced by Cancer Chemotherapy – Potential Regulatory Role of Chemokine CXCL12/Receptor CXCR4 Signalling
Current Molecular Medicine